Veracyte has posted four consecutive earnings beats averaging 48% upside surprise with 22% revenue growth and a Rule of 40 score of 41, but negative price momentum and an analyst target that has already been reached create an unfavorable near-term risk profile.
Thesis pillars
- Earnings Beat Streak Genomic Dx→Stable
- Rule Of 40 Growth Profile→Stable
- Product Supplier Dual Concentration→Stable
- +1 more pillar — see the Why tab for full reasoning
Veracyte, Inc. (VCYT) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $57.08: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 13%.
Veracyte offers molecular diagnostic tests for cancer — Decipher Prostate, Afirma (thyroid), Decipher Bladder, and Prosigna (breast) — through CLIA-certified labs in South San Francisco, San Diego, and Austin, Texas, with Decipher Prostate and Afirma generating the majority of... Read more
Sell if holding. Engine safety override at $57.08: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 13%. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.7/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news boost analyst 0.80, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Veracyte, Inc.
About Veracyte, Inc.
Decipher Prostate and Afirma account for the majority of Veracyte, Inc.'s revenue, delivered through CLIA-certified laboratories in South San Francisco, San Diego, and Austin, Texas. The company recorded net income of $66.4 million in 2025 against an accumulated deficit of $377.6 million; Medicare covers Afirma GSC for over 275 million enrollees and Decipher Prostate for over 215 million enrollees in the United States, with all four major tests assigned dedicated CPT Category I codes carrying finalized CLFS reimbursement rates.
Revenue comes from several payer sources: Medicare Fee-For-Service accounted for 34% of testing revenue in 2025, Medicare Advantage (billed through commercial payers) for 18%, Medicaid for 1%, and private commercial payers for 47%. Coverage for most tests is determined through the MolDX program administered by Palmetto GBA, a Medicare Administrative Contractor, under Local Coverage Determinations. Outside the U.S., Prosigna is sold as an IVD test to hospital and laboratory customers currently reimbursed in Germany, France, Spain, and 12 other countries; a multi-year agreement announced in 2023 with Illumina, Inc. covers development of certain tests on the NextSeq 550Dx platform for Canada, Europe, the Middle East, Asia Pacific, and Latin America. Competitors in prostate genomics include Myriad Genetics, Inc. and MDxHealth, SA; the company identifies Natera, Inc. as its primary MRD competition for muscle-invasive bladder cancer.
Show full overview
A PAMA rate-reset cycle poses a specific near-term risk to Veracyte's three highest-volume CPT codes. The Consolidated Appropriations Act, 2026 established a data reporting window of May 1 through July 31, 2026 using private-payer rates collected January through June 2025; if processed, updated CLFS rates would take effect January 1, 2027 through December 31, 2029. With Medicare FFS at 34% of 2025 testing revenue and the 10-K noting that decreases in Medicare payment rates may cascade to commercial payers that tie allowable amounts to Medicare's, a single PAMA rerate cycle could affect a substantial majority of total testing revenue simultaneously.
See also: Healthcare · Diagnostics & Research
From Veracyte, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-07-06Recent Developments — Veracyte, Inc.
Latest news
- NEWS Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance Singapore — Yahoo Finance Singapore positive
- NEWS Earnings Flash (VCYT) Veracyte, Inc. Posts Q1 Adjusted EPS $0.52 per Share - marketscreener.com — marketscreener.com positive
- NEWS Wall Street analysts think Veracyte (VCYT) could surge 39.16%: Read this before placing a bet - MSN — MSN positive
- NEWS Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet - Zacks Investment Researc — Zacks Investment Research positive
- NEWS A Look At Veracyte (VCYT) Valuation As New Decipher Bladder And Prostate Data Heads To AUA 2026 - Yahoo Finance — Yahoo Finance positive
Generated 2026-07-06T05:40:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductDecipher Prostate and Afirma tests10-K Item 1A: 'Most of our revenue to date has been derived from sales of our Decipher Prostate and Afirma laboratory developed tests (LDTs)'
- MEDIUMCustomerMedicare Fee-For-Service34%10-K Item 1: 'Medicare Fee-For-Service accounted for 34%, 33% and 35% of our testing revenue'
- MEDIUMregulatoryMolDX / Palmetto GBA10-K Item 1: 'Medicare coverage for most of Veracyte’s tests is determined through the MolDX program, administered by the MAC, Palmetto GBA'
- HIGHSuppliersole suppliers for reagents and equipment10-K Item 1A: 'We rely on sole suppliers for some of the reagents, equipment, and other materials used to perform or develop our tests'
Material Events(8-K, last 90d)
- 2026-03-16Item 5.02LOWOn March 16, 2026, Veracyte appointed Dr. Kevin Haas (age 40) as Chief Development and Technology Officer, effective March 24, 2026. Dr. Haas previously served as CTO of Myriad Genetics, Inc. since February 2021. Offer letter provides $500,000 base salary and $1.5M RSU award.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $57.08: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 13%. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $53.08. Score 5.7/10, moderate confidence.
Take-profit target: $59.69 (+4.6% upside). Prior stop was $53.08. Stop-loss: $53.08.
Concentration risk — Product: Decipher Prostate and Afirma tests; Concentration risk — Supplier: sole suppliers for reagents and equipment; Target reached (-22.9% upside).
Veracyte, Inc. trades at a P/E of 52.9 (forward 30.0). TrendMatrix value score: 4.3/10. Verdict: Sell.
18 analysts cover VCYT with a consensus score of 4.2/5. Average price target: $51.
What does Veracyte, Inc. do?Veracyte offers molecular diagnostic tests for cancer — Decipher Prostate, Afirma (thyroid), Decipher Bladder, and...
Veracyte offers molecular diagnostic tests for cancer — Decipher Prostate, Afirma (thyroid), Decipher Bladder, and Prosigna (breast) — through CLIA-certified labs in South San Francisco, San Diego, and Austin, Texas, with Decipher Prostate and Afirma generating the majority of revenue. The company recorded net income of $66.4 million in 2025, billing Medicare, Medicare Advantage, Medicaid, and commercial payers that collectively fund oncology genomic testing.